EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

Eva-Maria Willing iD, Claudia Vollbrecht, Christine Vössing, Peggy Weist iD, Simon Schallenberg iD, Johanna M Herbst, Stefanie Schatz iD, Balázs Jóri iD, Guillaume Bataillon, Philipp Harter iD, Vanda Salutari, Antonio Gonzáles Martin iD und 22 weitere

Cancers · 30.06.2023 · 15 (13) · 3445

DOI: 10.3390/cancers15133445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 30.06.2023. Verfasst von Eva-Maria Willing und 33 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Hämatopathologie Hamburg, 22547 Hamburg, Germany. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The worldwide approval of the combination maintenance therapy of olaparib and bevacizumab in advanced high-grade serous ovarian cancer requires complex molecular diagnostic assays that are sufficiently robust for the routine detection of driver mutations in homologous recombination repair (HRR) genes and genomic instability (GI), employing formalin-fixed (FFPE) paraffin-embedded tumor samples without matched normal tissue. We therefore established a DNA-based hybrid capture NGS assay and an associated bioinformatic pipeline that fulfils our institution’s specific needs. The assay´s target regions cover the full exonic territory of relevant cancer-related genes and HRR genes and more than 20,000 evenly distributed single nucleotide polymorphism (SNP) loci to allow for the detection of genome-wide allele specific copy number alterations (CNA). To determine GI status, we implemented an %CNA score that is robust across a broad range of tumor cell content (25–85%) often found in routine FFPE samples. The assay was established using high-grade serous ovarian cancer samples for which BRCA1 and BRCA2 mutation status as well as Myriad MyChoice homologous repair deficiency (HRD) status was known. The NOGGO (Northeastern German Society for Gynecologic Oncology) GIS (GI-Score) v1 assay was clinically validated on more than 400 samples of the ENGOT PAOLA-1 clinical trial as part of the European Network for Gynaecological Oncological Trial groups (ENGOT) HRD European Initiative. The “NOGGO GIS v1 assay” performed using highly robust hazard ratios for progression-free survival (PFS) and overall survival (OS), as well a significantly lower dropout rate than the Myriad MyChoice clinical trial assay supporting the clinical utility of the assay. We also provide proof of a modular and scalable routine diagnostic method, that can be flexibly adapted and adjusted to meet future clinical needs, emerging biomarkers, and further tumor entities.

Schlagwörter

Stichwörter der Autor:innen

BRCA1BRCA2DNA repairHRDHRRLOHOSPAOLA-1PARP inhibitionPARPiPFSbreast cancerdiagnosticsgenomic instabilityhomologous repair deficiency

Autor:innen und Institutionen

  • Institut für Hämatopathologie Hamburg, 22547 Hamburg, Germany.
  • Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie NOGGO e. V., 13359 Berlin, Germany.
  • Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
  • Lungenkrebsmedizin Oldenburg, GbR, 26121 Oldenburg, Germany.
  • Department of Pathology, Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole, 31100 Toulouse, France.
  • Kliniken Essen Mitte, 45276 Essen, Germany.

ORCID-Profile: Eva-Maria Willing, Peggy Weist, Simon Schallenberg, Stefanie Schatz, Balázs Jóri, Philipp Harter, Antonio Gonzáles Martin, Ignace Vergote, Regina Berger, Markus Falk, Isabelle Ray-Coquard, Jalid Sehouli, Eric Pujade-Lauraine

Zitieren

APA

Willing, E. M., Vollbrecht, C., Vössing, C., Weist, P., Schallenberg, S., Herbst, J. M., Schatz, S., Jóri, B., Bataillon, G., Harter, P., Salutari, V., Martin, A. G., Vergote, I., Colombo, N., Roeper, J., Berg, T., Berger, R., Kah, B., Noettrup, T. J., …, & Heukamp, L. C. (2023). Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation. Cancers, 15(13), 3445. https://doi.org/10.3390/cancers15133445

Vancouver

Willing EM, Vollbrecht C, Vössing C, Weist P, Schallenberg S, Herbst JM, et al. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation. Cancers. 2023;15(13):3445. doi:10.3390/cancers15133445

BibTeX
@article{Willing2023,
  author = {Willing, Eva-Maria and Vollbrecht, Claudia and Vössing, Christine and Weist, Peggy and Schallenberg, Simon and Herbst, Johanna M and Schatz, Stefanie and Jóri, Balázs and Bataillon, Guillaume and Harter, Philipp and Salutari, Vanda and Martin, Antonio Gonzáles and Vergote, Ignace and Colombo, Nicoletta and Roeper, Julia and Berg, Tobias and Berger, Regina and Kah, Bettina and Noettrup, Trine Jakobi and Falk, Markus and Arndt, Kathrin and Polten, Andreas and Ray-Coquard, Isabelle and Selzam, Franziska and Pirngruber, Judith and Schmidt, Stefanie and Hummel, Michael and Tiemann, Markus and Horst, David and Sehouli, Jalid and Pujade-Lauraine, Eric and Tiemann, Katharina and Braicu, Elena Ioana and Heukamp, Lukas C},
  title = {Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {13},
  pages = {3445},
  doi = {10.3390/cancers15133445}
}
Kostenlos starten →